Neuroleptic withdrawal with remitted schizophrenics: A naturalistic follow-up study

Psychiatry

Volumn 70, Issue 1, 2007, Pages 68-79

  Nishikawa, Tadashi ^a   Hayashi, Teruo ^b   Koga, Itsuyuki ^a   Uchida, Yasunori ^a  

^a Seiwakai Nishikawa Hospital   (Japan)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLONAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; RISPERIDONE; SULPIRIDE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; DELUSION; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MEIGE DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; OUTCOME ASSESSMENT; PARKINSONISM; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; ADOLESCENT; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; REMISSION INDUCTION; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34249655132     PISSN: 00332747     EISSN: 1943281X     Source Type: Journal    
DOI: 10.1521/psyc.2007.70.1.68     Document Type: Article

References (35)

1. American Psychiatric Association (1997). Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 154 (April suppl.).
2. Beasley, C. M. Jr., Sutton, V.K., Taylor, C.C., Sethuraman, G., Dossenbach, M., & Naber, D. (2006). Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment? Journal of Clinical Psychopharmacology, 26, 40-44.
3. Bleuler, M. (1972). Die schizophrenen Geistesstorungen im Lichte langjahringer Kranken- und Familiengeschichten. Stuttgart: Thieme.
4. Breier, A., Schreiber, J.L., Dyer, J., & Pickar, D. (1991). National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Archives of General Psychiatry, 48, 239-246.
5. Buchanan, R.W., Kirkpatrick, B., Summerfelt, A., Hanlon, T.E., Levine, J., & Carpenter, W.T., Jr. (1992). Clinical predictors of relapse following neuroleptic withdrawal. Biological Psychiatry, 32, 72-78.
6. Carpenter, W.T. Jr. (1996). Maintenance therapy of persons with schizophrenia. Journal of Clinical Psychiatry, 57 Suppl. 9, 10-18.
7. Carpenter, W.T., Jr., Hanlon, T.E., Heinrichs, D.W., Summerfelt, A.T., Kirkpatrick, B., Levine, J., & Buchanan, R.W. (1990). Continuous versus targeted medication in schizophrenic outpatients: Outcome results. American Journal of Psychiatry, 147, 1138-1148.
8. Childers, S.E., & Harding, C.M. (1990) Gender, premorbid, social functioning, and long-term outcome in DSM III schizophrenia. Schizophrenia Bulletin. 16, 309-318.
9. Crow, T.J., MacMillan, J.F., Johnson, A.L., & Johnstone, E.C. (1986). A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120-127.
10. Csernansky, J.G., Mahmoud, R., & Brenner, R.; Risperidone-USA-79 Study Group. (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine, 346, 16-22.
11. Csernansky, J.G., & Schuchart, E.K. (2002). Relapse and rehospitalisation rates in patients with schizophrenia: Effects of second generation antipsychotics. CNS Drugs, 16, 473-484.
12. Davis, J.M. (1975). Overview: Maintenance therapy in psychiatry. I. Schizophrenia. American Journal of Psychiatry, 132, 1237-1245.
13. Geddes, J., Mercer, G., Frith, C.D., MacMillan. F., Owens, D.G., & Johnstone, E.C. (1994). Prediction of outcome following a first episode of schizophrenia. A follow-up study of Northwick Park first episode study subjects. British Journal of Psychiatry, 165, 664-668.
14. Harris, M.J., Heaton, R.K., Schalz, A., Bailey, A., & Patterson, T.L. (1997). Neuroleptic dose reduction in older psychotic patients. Schizophrenia Research, 27, 241-248.
15. Hayashi, T., Yamawaki, S., Nishikawa, T., & Jeste, D.V. (1995). Usage and side effects of neuroleptics in elderly Japanese patients. American Journal of Geriatric Psychiatry, 3, 308-316.
16. Herz, M.I., Glazer, W.M., Mostert, M.A., Sheard, M.A., Szymanski, H.V., Hafez, H., Mirza, M., & Vana, J. (1991). Intermittent vs. maintenance medication in schizophrenia. Two-year results. Archives of General Psychiatry, 48, 333-339.
17. Hogarty, G.E., McEvoy, J.P., Munetz, M., DiBarry, A.L., Bartone, P., Cather, R., Cooley, S.J., Ulrich, R.F., Carter, M., & Madonia, M.J. (1988). Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Archives of General Psychiatry, 45, 797-805.
18. Jeste, D.V., Palmer, B.W., & Harris, M.J. (1999). Neuroleptic discontinuation in clinical and research settings: Scientific issues and ethical dilemmas. Biological Psychiatry, 46, 1050-1059.
19. Johnstone, E. C. (1991). What is crucial for the long-term outcome of schizophrenia? In H. Hafner & W.F. Gattaz (Eds.) Search for the Causes of Schizophrenia, Vol. II (pp. 67-76). Berlin: Springer.
20. Jolley, A.G., Hirsch, S.R., Morrison, E., McRink, A., & Wilson, L. (1990). Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years. British Medical Journal, 301, 837-842.
21. Kane, J.M. (1990). Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica Supplementum, 358, 151-157.
22. Kane, J.M. (1999). Pharmacologic treatment of schizophrenia. Biological Psychiatry, 46, 1396-1408.
23. Lam, R.W., Jeste, S.D., & Jeste, D.V. (1988). Preventing neuroleptic-induced tardive dyskinesia in adults and children. Encephale, 14, 251-255.
24. Lieberman, J.A., Alvir, J., Geisler, S., Ramos-Lorenzi, J., Woerner, M., Novacenko, H., Cooper, T., & Kane, J.M. (1994). Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology, 11, 107-118.
25. Marder, S.R., Van Putten, T., Mintz, J., Lebell, M., McKenzie, J., & May, P.R. (1987). Low-and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Archives of General Psychiatry, 44, 518-521.
26. McGorry, P.D., Yung, A.R., Phillips, L.J., Yuen, H.P., Francey, S., Cosgrave, E.M., Germano, D., Bravin, J., McDonald, T., Blair, A., Adlard, S., & Jackson, H. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59, 921-928.
27. Meltzer, H.Y. (1999). Outcome in schizophrenia: Beyond symptom reduction. Journal of Clinical Psychiatry, 60 (Suppl. 3), 3-7.
28. Nishikawa, T., Sato, M., Hayashi, T., Tanaka, M., Tanaka, S., Koga, I., Uchida, Y., & Kawahara, R. (1997). Intermittent withdrawal program of neuroleptics with sulpiride in remitted schizophrenic outpatients. Human Psychopharmacology Clinical Experiments, 12, 510-511.
29. Nishikawa, T., Tanaka, M., Koga, I., & Uchida, Y. (1998). A case of Meige and neck dystonia appearing following very low dose sulpiride. Human Psychophamacology Clininical Experiments, 13, 59-61.
30. Nishikawa, T., Tanaka, M., Tsuda, A., Koga, I., & Uchida, Y. (1989). Prophylactic effects of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of timiperone and sulpiride. Biological Psychiatry, 25, 861-866.
31. Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., & Lieberman, J.A. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241-247.
32. Stephens, J.H. (1978). Long-term prognosis and follow up in schizophrenia. Schizophrenia Bulletin, 4, 25-47.
33. Tawara, Y., Nishikawa, T., Koga, I., Uchida, Y., & Yamawaki, S. (1997). Transient and intermittent oral dyskinesia appearing in a young woman ten days after neuroleptic treatment. Clinical Neuropharmacology, 20, 175-178.
34. Uchida, Y., Tsuda, A., Koga, I., Sakamoto, T., and Nishikawa, T. (1987). A follow-up study on outpatients with psychosis: Analysis of prognosis of drop-out cases. Seishin-igaku (in Japanese), 29, 1081-1090.
35. van Kammen, D.P., Kelley, M.E., Gurklis, J.A., Gilbertson, M.W., Yao, J.K., Condray, R., & Peters, J.L. (1996). Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients. Neuropsychopharmacology, 14, 275-283.